$QNCX
Quince Therapeutics, Inc.

2019 Q1 Form 10-Q Financial Statement

#000156459019022340 Filed on June 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.250M $350.0K
YoY Change 257.14%
% of Gross Profit
Research & Development $4.825M $2.413M
YoY Change 99.96%
% of Gross Profit
Depreciation & Amortization -$10.00K $10.00K
YoY Change -200.0%
% of Gross Profit
Operating Expenses $6.075M $2.760M
YoY Change 120.11%
Operating Profit -$6.075M -$2.760M
YoY Change 120.11%
Interest Expense $390.0K $599.0K
YoY Change -34.89%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.680M -$3.380M
YoY Change 68.05%
Income Tax
% Of Pretax Income
Net Earnings -$5.681M -$3.377M
YoY Change 68.23%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.22 -$0.13
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.04M
YoY Change
Cash & Equivalents $20.63M $4.404M
Short-Term Investments $38.41M
Other Short-Term Assets $387.0K
YoY Change
Inventory
Prepaid Expenses $243.0K
Receivables
Other Receivables
Total Short-Term Assets $63.79M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $314.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.400M
YoY Change
Other Assets $261.0K
YoY Change
Total Long-Term Assets $6.806M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $63.79M
Total Long-Term Assets $6.806M
Total Assets $70.60M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.946M
YoY Change
Accrued Expenses $1.724M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.010M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $500.0K
YoY Change
Total Long-Term Liabilities $500.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.010M
Total Long-Term Liabilities $500.0K
Total Liabilities $4.485M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$38.51M
YoY Change
Common Stock $502.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$38.03M -$23.64M
YoY Change
Total Liabilities & Shareholders Equity $70.60M
YoY Change

Cashflow Statement

Concept 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$5.681M -$3.377M
YoY Change 68.23%
Depreciation, Depletion And Amortization -$10.00K $10.00K
YoY Change -200.0%
Cash From Operating Activities -$7.216M -$3.177M
YoY Change 127.13%
INVESTING ACTIVITIES
Capital Expenditures $51.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $51.32M $0.00
YoY Change
Cash From Investing Activities $3.164M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 64.00K 238.0K
YoY Change -73.11%
NET CHANGE
Cash From Operating Activities -7.216M -3.177M
Cash From Investing Activities 3.164M 0.000
Cash From Financing Activities 64.00K 238.0K
Net Change In Cash -3.988M -2.939M
YoY Change 35.69%
FREE CASH FLOW
Cash From Operating Activities -$7.216M -$3.177M
Capital Expenditures $51.00K $0.00
Free Cash Flow -$7.267M -$3.177M
YoY Change 128.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20634000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24872000
CY2019Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
38410000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
46844000
CY2019Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
250000
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4496000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
868000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
63790000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
72584000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
314000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
283000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
815000
CY2019Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
5416000
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
261000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10000
CY2019Q1 us-gaap Assets
Assets
70596000
CY2018Q4 us-gaap Assets
Assets
72877000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1946000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
495000
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1724000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
962000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
340000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4010000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1457000
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
475000
CY2019Q1 us-gaap Liabilities
Liabilities
4485000
CY2018Q4 us-gaap Liabilities
Liabilities
1457000
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
4000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
498000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
245000
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-23000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-49000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38506000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32825000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-38027000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-32626000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70596000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72877000
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
24794114
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
24794114
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3566923
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3412366
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3566923
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3412366
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4825000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2413000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1250000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
347000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
6075000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
2760000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6075000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2760000
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
394000
CY2018Q1 us-gaap Interest Expense
InterestExpense
599000
CY2018Q1 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
-18000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5681000
CY2019Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
26000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5655000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3377000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.61
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.01
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3521045
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3359989
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
64000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
190000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
26000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-20280000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-23644000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-5681000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-3377000
CY2018Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
159000
CY2019Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
92000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
190000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
13000
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
19000
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8000
CY2018Q1 us-gaap Accretion Expense
AccretionExpense
440000
CY2019Q1 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
171000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3628000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
80000
CY2019Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
250000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-82000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
762000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-276000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7216000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3177000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1451000
CY2019Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
25585000
CY2019Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
28800000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
51000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3164000
CY2018Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
250000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
64000
CY2018Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
12000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
238000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3988000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2939000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24872000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7393000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20884000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4454000
CY2019Q1 crtx Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities
RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities
815000
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as related disclosure of contingent assets and liabilities. The most significant estimates used in the Company&#8217;s financial statements relate to the determination of the fair value of common stock and stock-based awards and other issuances, valuation of derivative instruments, accruals for research and development costs, useful lives of long-lived assets, stock-based compensation and related assumptions, the incremental borrowing rate for leases and income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from the Company&#8217;s estimates.</p>
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
13613000
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
60457000
CY2019Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q1 crtx Entity Date Of Incorporation
EntityDateOfIncorporation
2012-06
CY2019Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
59000000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4404000
CY2018Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2019Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
60395000
CY2019Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2019Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
28000
CY2019Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
60372000
CY2019Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
16546000
CY2019Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
60372000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
60506000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
49000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
60457000
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2019Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
243000
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
13000
CY2019Q1 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
1128000
CY2018Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
34000
CY2019Q1 crtx Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
2678000
CY2018Q4 crtx Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
587000
CY2019Q1 crtx Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
60000
CY2018Q4 crtx Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
166000
CY2019Q1 us-gaap Other Assets Current
OtherAssetsCurrent
387000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
68000
CY2019Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
428000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
378000
CY2019Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
114000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
95000
CY2019Q1 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
182000
CY2018Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
483000
CY2019Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
385000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
75000
CY2019Q1 crtx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1136000
CY2018Q4 crtx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
380000
CY2019Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
21000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
24000
CY2018Q2 crtx Number Of Investors
NumberOfInvestors
1
CY2018Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
0
CY2018Q2 crtx Repurchase Option Percentage
RepurchaseOptionPercentage
1.00
CY2018Q2 crtx Operating Leases Period
OperatingLeasesPeriod
P3Y
CY2019Q1 crtx Unvested Shares Subject To Repurchase Option
UnvestedSharesSubjectToRepurchaseOption
89006
CY2019Q1 crtx Operating Lease Future Rent Expense
OperatingLeaseFutureRentExpense
856000
CY2019Q1 crtx Operating Lease Remaining Lease Term On Straight Line Basis
OperatingLeaseRemainingLeaseTermOnStraightLineBasis
P28M
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
275000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
366000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
214000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
855000
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
40000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
815000
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0400
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2019Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3155694
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P4Y
CY2014Q2 crtx Percentage Of Royalty Rate Of Gross Revenues
PercentageOfRoyaltyRateOfGrossRevenues
0.03
CY2018Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2019Q1 crtx Provision For Income Taxes
ProvisionForIncomeTaxes
0
CY2019Q1 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
28000000
CY2019Q1 crtx Operating Loss Carryforward Expiration Year
OperatingLossCarryforwardExpirationYear
2034
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20250790
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9916556

Files In Submission

Name View Source Status
0001564590-19-022340-index-headers.html Edgar Link pending
0001564590-19-022340-index.html Edgar Link pending
0001564590-19-022340.txt Edgar Link pending
0001564590-19-022340-xbrl.zip Edgar Link pending
crtx-10q_20190331.htm Edgar Link pending
crtx-20190331.xml Edgar Link completed
crtx-20190331.xsd Edgar Link pending
crtx-20190331_cal.xml Edgar Link unprocessable
crtx-20190331_def.xml Edgar Link unprocessable
crtx-20190331_lab.xml Edgar Link unprocessable
crtx-20190331_pre.xml Edgar Link unprocessable
crtx-ex311_7.htm Edgar Link pending
crtx-ex312_6.htm Edgar Link pending
crtx-ex321_8.htm Edgar Link pending
crtx-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending